Biologic, cytogenetic, and molecular factors in mesothelial proliferations

Ultrastructural Pathology

Volumn 30, Issue 1-2, 2006, Pages 19-30

  Hicks, John ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Biology; Cell cycle; Cytogenetics; Epidemiology; Growth factors; Mesothelioma; Molecular pathology; SV40; Tumor suppressor genes

Indexed keywords

ASBESTOS; CELLULAR RETINOL BINDING PROTEIN 1; CYCLIN D2; CYCLOOXYGENASE 2; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; GEFITINIB; GRAMICIDIN D; GUANOSINE TRIPHOSPHATASE; MESOTHELIN; PACLITAXEL; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SYNDECAN 1; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VINCRISTINE; TUMOR MARKER;

ADENOCARCINOMA; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RESISTANCE; CANCER SURGERY; CARCINOGENESIS; CELL PROLIFERATION; CHROMOSOME SEGREGATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONFERENCE PAPER; CYTOGENETICS; DIAGNOSTIC VALUE; DNA DAMAGE; DNA SEQUENCE; DOWN REGULATION; ENVIRONMENTAL EXPOSURE; EPIDEMIC; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE EXPRESSION; GENE MAPPING; GENE SILENCING; GENE THERAPY; GENOMICS; HUMAN; IMMUNOCYTOCHEMISTRY; KARYOTYPE; MESOTHELIOMA; MICROARRAY ANALYSIS; MOLECULAR GENETICS; MONOSOMY; NONHUMAN; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; SEROPREVALENCE; SIGNAL TRANSDUCTION; SIMIAN VIRUS 40; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; CHROMOSOME ANALYSIS; EPITHELIUM; GENETICS; METABOLISM; MOLECULAR BIOLOGY; PATHOLOGY; REVIEW;

ASBESTOS; CELL PROLIFERATION; CYTOGENETIC ANALYSIS; EPITHELIUM; HUMANS; MESOTHELIOMA; MOLECULAR BIOLOGY; TUMOR MARKERS, BIOLOGICAL;

EID: 33645994867     PISSN: 01913123     EISSN: 15210758     Source Type: Journal    
DOI: 10.1080/01913120500313168     Document Type: Conference Paper

References (47)

1. Price B, Ware A. Mesothelioma trends in the United States: an update based on surveillance, epidemiology, and end results program data for 1973 through 2003. Am J Epidemiol. 2004;159:107-112.
2. Krismann M, Muller K, Jaworska M, Johnen G. Pathological anatomy and molecular pathology. Lung Cancer. 2004;45S:S29-S33.
3. Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol. 2002;29:2-17.
4. Mutti L, Broaddus VC. Malignant mesothelioma as both a challenge and an opportunity. Oncogene. 2004;23:9155-9161.
5. Burgers J, Damhuis R. Prognostic factors in malignant mesothelioma. Lung Cancer. 2004;45S:S49-S54.
6. Sandberg A, Bridges J. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: mesothelioma. Cancer Genet Cytogenet. 2001;127:93-110.
7. Burmeister B, Schwerdtle T, Poser I, et al. Effects of asbestos on initiation of DNA damage, induction of DNA-strand breaks, p53 expression and apoptosis in primary SV40-transformed and malignant human mesothelioma cells. Mutat Res. 2004;558:81-92.
8. Murthy S, Testa J. Asbestos, chromosomal deletions and tumor suppressor gene alterations in human malignant mesothelioma. J Cell Physiol. 1999;199:150-157.
9. Kamp DW, Weitzman SA. The molecular basis of asbestos induced lung injury. Thorax. 1999;54:638-652.
10. Unfried K, Schurkes C, Abel J. Distinct spectrum of mutations induced by crocidolite asbestos: clue for 8-hydroxydeoxyguanosine-dependent mutagenesis in vivo. Cancer Res. 2002;62:99-104.
11. Dammann R, Schagdarsurengin U, Strunnikova M, et al. Epigenetic inactivation of the RAS-association domain family 1 (RASSFIA) gene and its function in human carcinogenesis. Histol Histopathol. 2003;18:665-677.
12. Dobra K, Nurminen M, Hjerpe A. Growth factors regulate the expression profile of their syndecan co-receptors and the differentiation of mesothelioma cells. Anticancer Res. 2003;23:2435-2444.
13. Kumar-Singh S, Jacobs W, Dhaene K, et al. Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression and clinical outcome. J Pathol. 1998;186:300-305.
14. Singhai S, Wiewrodt B, Malden L, et al. Gene expression profiling of malignant mesothelioma. Clin Cancer Res. 2003;9:3080-3097.
15. Gordon GJ, Jensen RV, Hsial LL, et al. Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst. 2003;95:598-605.
16. Gordon GJ, Jensen RV, Hsial LL, et al. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res. 2002;62:4963-4967.
17. Pass HI, Liu Z, Wali A, Bueno R, et al. Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res. 2004;10:849-859.
18. Kettunen E, Nissen A, Ollikainen I, et al. Gene expression profiling of malignant mesothelioma cell lines: cDNA array study. Int J Cancer 2001;91:492-496.
19. Gulyas M, Hjerpe A. Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium. J Pathol 2003;199:479-487.
20. Hecht J, Lee B, Pinkus J, Pinkus G. The value of Wilms tumor susceptibility gene 1 in cytologic preparations as a marker for malignant mesothelioma. Cancer Cytopathol. 2002;96:105-109.
21. Scharnhorst, van der Eb AJ, Jochemsen AG. WT1 proteins: functions in growth and differentiation. Gene. 2001;273:141-161.
22. Cheng JQ, Lee WC, Klein MA, Cheng GZ, Jhanwar SC, Testa JR. Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation. Genes Chromosomes Cancer. 1999;24:238-242.
23. Hegmns J, Bard M, Hemmes A, et al. Proteomic analysis of exosomes secreted by human mesothelioma cells. Am J Pathol. 2004;164:1807-1815.
24. Hoang C, D'Cunha J, Kratzke M, et al. Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest. 2004;125:1843-1852.
25. Illei PB, Rusch VW, Zakowski MF, Ladanyi F. Homozygous deletion of CDKN2A and co-deletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res. 2003;9:2108-2113.
26. Mohiuddin I, Cao X, Ozvaran MK, Zumstein L, Chada S, Smythe WR. Phosphatase and tensin analog gene overexpression engenders cell death in human malignant mesothelioma cells via inhibition of AKT phosphorylation. Ann Surg Oncol. 2002;9:310-316.
27. Neuzil J, Swettenham E, Gellert N. Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xl down-regulation. Biochem Biophys Res Commun. 2004;314:186-191.
28. Puntoni R, Filiberti R, Cerrano PG, Neri M, Andreatta R, Bonassi S. Implementation of a molecular epidemiology approach to human pleural malignant mesothelioma. Mutat Res. 2003;544:385-396.
29. Pylkkanen L, Wolff H, Stjernvall T, Knuuttila A, Anttila S, Husgafvel-Pursiainen K. Reduced Fhit protein expression in human malignant mesothelioma. Virchows Arch. 2004;444:43-48.
30. Uematsu K, Kanazawa S, You L, et al. Wnt pathway activation in mesothelioma: evidence of disheveled overexpression and transcriptional activity of beta-catenin. Cancer Res. 2003;4547-4551.
31. You L, He B, Uematsu K, et al. Inhibition of wnt-1 signaling induces apoptosis in beta-catenin deficient mesothelioma cells. Cancer Res. 2004;64:3474-3478.
32. Vasef MA, Sheibani K. p63 is a useful marker in distinguishing pleural malignant mesothelioma (PMM) from pulmonary squamous cell carcinoma (SCC) involving pleura. Mod Pathol. 2005;18:319A.
33. Vilchez RA, Butel JS. Emergent human pathogen simian virus 40 and its role in cancer. Clini Microbiol Rev. 2004;17:495-508.
34. Vilchez RA, Killen DE, Butel JS, Zander DS, Popper HH, Cagle PT. Immunophenotypic profile of SV40 induced diffuse malignant mesothelioma (DMM) in hamsters: similarities to human DMM. Mod Pathol. 2005;18:320A.
35. Baldi A, Groeger AM, Esposito V, et al. Expression of p21 in SV40 large t antigen positive human pleural mesothelioma: relationship with survival. Thorax. 2002;57:353-356.
36. Mayall FG, Jacobson G, Wilkins R. Mutation of p53 gene and SV40 sequences in asbestos associated and non-asbestos associated mesotheliomas. J Clin Pathol. 1999;52:291-293.
37. Zeren EH, Ergin M, Gumurdulu D, Demirag F, Cagle P. SV40 and malignant mesothelioma: a molecular and immunohistochemical study of 83 cases from USA and two different regions of Turkey. Mod Pathol. 2005;18:322A,
38. Suzuki M, Toyooka S, Shivapurkar N, et al. Aberrant methylation profile of human malignant mesotheliomas and its relationship to SV40 infection. Oncogene. 2004;1-7.
39. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004;10:3937-3942.
40. Ordonez NG. Application of mesothelin immunostaining in diagnosis. Am J Surg Pathol. 2003;27:1418-1428.
41. Robinson BWS, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003;362:1612-1616.
42. Baldi A, Santini D, Vasaturo F, et al. Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma. Thorax. 2004;59:428-433.
43. Cai Y, Roggli V, Mark E, Cagle P, Fraire A. Transforming growth factor alpha and epidermal growth factor receptor in reactive and malignant mesothelial proliferations. Arch Pathol Lab Med. 2004;128:68-70.
44. She Y, Lee F, Chen J, et al. The epidermal growth factor receptor tyrosine kinase inhibitor ZD 1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index. Clin Cancer Res. 2003;9:3773-3778.
45. Vasef MA, Tafazzoli A, Sheibani K. Epidermal growth factor receptor (EGFR) gene amplification in pleural malignant mesothelioma (MM): a chromogenic in situ hybridization (CISH) assay. Mod Pathol. 2005;18:320A.
46. Sienko A, Znader DS, Killen D, et al. D2-40 is a novel new marker of malignant mesothelioma (MM): tissue microarray study of 45 MM versus 409 lung carcinomas and primary non-mesothelial neoplasms of the pleura and chest wall. Mod Pathol. 2005;18:318A.
47. Allen TC, Sienko A, Zander DS, Singhal N, Killen DE, Haque A, Cagle PT. DAX-1 and androgen receptor expression in diffuse malignant mesothelioma: possible targets of hormonal therapy. Mod Pathol. 2005;18:307A.